405 related articles for article (PubMed ID: 18035189)
21. Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901.
Czuczman MS; Porcu P; Johnson J; Niedzwiecki D; Kelly M; Hsi ED; Cook JR; Canellos G; Cheson BD;
Leuk Lymphoma; 2007 Jan; 48(1):97-103. PubMed ID: 17325852
[TBL] [Abstract][Full Text] [Related]
22. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ; Goodin S
Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
[TBL] [Abstract][Full Text] [Related]
23. A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies.
Boddu PC; Senapati J; Ravandi-Kashani F; Jabbour EJ; Jain N; Ayres M; Chen Y; Keating MJ; Kantarjian HM; Gandhi V; Kadia TM
Cancer; 2023 Feb; 129(4):580-589. PubMed ID: 36448227
[TBL] [Abstract][Full Text] [Related]
24. Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer.
Steinberg M
Clin Ther; 2008 Sep; 30(9):1590-617. PubMed ID: 18840366
[TBL] [Abstract][Full Text] [Related]
25. Nelarabine: new drug. T-lymphoblastic leukaemia/lymphoma: more evaluation needed.
Prescrire Int; 2009 Feb; 18(99):3-5. PubMed ID: 19382393
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies.
Kisor DF; Plunkett W; Kurtzberg J; Mitchell B; Hodge JP; Ernst T; Keating MJ; Gandhi V
J Clin Oncol; 2000 Mar; 18(5):995-1003. PubMed ID: 10694549
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells.
Gandhi V; Plunkett W; Weller S; Du M; Ayres M; Rodriguez CO; Ramakrishna P; Rosner GL; Hodge JP; O'Brien S; Keating MJ
J Clin Oncol; 2001 Apr; 19(8):2142-52. PubMed ID: 11304766
[TBL] [Abstract][Full Text] [Related]
28. 2-Amino-6-methoxypurine arabinoside: an agent for T-cell malignancies.
Lambe CU; Averett DR; Paff MT; Reardon JE; Wilson JG; Krenitsky TA
Cancer Res; 1995 Aug; 55(15):3352-6. PubMed ID: 7614470
[TBL] [Abstract][Full Text] [Related]
29. Complete hematologic and cytogenetic response to 2-amino-9-beta-D-arabinosyl-6-methoxy-9H-guanine in a patient with chronic myelogenous leukemia in T-cell blastic phase: a case report and review of the literature.
Aguayo A; Cortes JE; Kantarjian HM; Beran M; Gandhi V; Plunkett W; Kurtzberg J; Keating MJ
Cancer; 1999 Jan; 85(1):58-64. PubMed ID: 9921974
[TBL] [Abstract][Full Text] [Related]
30. Neurotoxic side effects in children with refractory or relapsed T-cell malignancies treated with nelarabine based therapy.
Kuhlen M; Bleckmann K; Möricke A; Schrappe M; Vieth S; Escherich G; Bronsema A; Vonalt A; Queudeville M; Zwaan CM; Ebinger M; Debatin KM; Klingebiel T; Koscielniak E; Rossig C; Burkhardt B; Kolb R; Eckert C; Borkhardt A; von Stackelberg A; Chen-Santel C
Br J Haematol; 2017 Oct; 179(2):272-283. PubMed ID: 28771662
[TBL] [Abstract][Full Text] [Related]
31. Nelarabine in the treatment of refractory T-cell malignant diseases.
Kline J; Larson RA
Expert Opin Pharmacother; 2006 Sep; 7(13):1791-9. PubMed ID: 16925505
[TBL] [Abstract][Full Text] [Related]
32. Novel purine nucleoside analogues for hematological malignancies.
Korycka A; Lech-Marańda E; Robak T
Recent Pat Anticancer Drug Discov; 2008 Jun; 3(2):123-36. PubMed ID: 18537755
[TBL] [Abstract][Full Text] [Related]
33. Three new drugs for acute lymphoblastic leukemia: nelarabine, clofarabine, and forodesine.
Larson RA
Semin Oncol; 2007 Dec; 34(6 Suppl 5):S13-20. PubMed ID: 18086342
[TBL] [Abstract][Full Text] [Related]
34. Pharmacological and biochemical strategies to increase the accumulation of arabinofuranosylguanine triphosphatein primary human leukemia cells.
Rodriguez CO; Legha JK; Estey E; Keating MJ; Gandhi V
Clin Cancer Res; 1997 Nov; 3(11):2107-13. PubMed ID: 9815603
[TBL] [Abstract][Full Text] [Related]
35. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.
Yamamoto K; Utsunomiya A; Tobinai K; Tsukasaki K; Uike N; Uozumi K; Yamaguchi K; Yamada Y; Hanada S; Tamura K; Nakamura S; Inagaki H; Ohshima K; Kiyoi H; Ishida T; Matsushima K; Akinaga S; Ogura M; Tomonaga M; Ueda R
J Clin Oncol; 2010 Mar; 28(9):1591-8. PubMed ID: 20177026
[TBL] [Abstract][Full Text] [Related]
36. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801.
DeAngelo DJ; Yu D; Johnson JL; Coutre SE; Stone RM; Stopeck AT; Gockerman JP; Mitchell BS; Appelbaum FR; Larson RA
Blood; 2007 Jun; 109(12):5136-42. PubMed ID: 17344466
[TBL] [Abstract][Full Text] [Related]
37. Nelarabine.
Sanford M; Lyseng-Williamson KA
Drugs; 2008; 68(4):439-47. PubMed ID: 18318562
[TBL] [Abstract][Full Text] [Related]
38. A Phase I Dose-Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low-Grade or Intermediate-Grade B-Cell or T-Cell Lymphoma.
Foss FM; Parker T
Oncologist; 2018 Apr; 23(4):397-e30. PubMed ID: 29438091
[TBL] [Abstract][Full Text] [Related]
39. Plasma and cerebrospinal fluid pharmacokinetics of nelarabine in nonhuman primates.
Berg SL; Brueckner C; Nuchtern JG; Dauser R; McGuffey L; Blaney SM
Cancer Chemother Pharmacol; 2007 May; 59(6):743-7. PubMed ID: 16953392
[TBL] [Abstract][Full Text] [Related]
40. Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma.
Abaza Y; M Kantarjian H; Faderl S; Jabbour E; Jain N; Thomas D; Kadia T; Borthakur G; D Khoury J; Burger J; Wierda W; O'Brien S; Konopleva M; Ferrajoli A; Kebriaei P; Dabaja B; Kornblau S; Alvarado Y; Daver N; Pemmaraju N; Bose P; Thompson P; Al Azzawi H; Kelly M; Garris R; Jain P; Garcia-Manero G; Cortes J; Ravandi F
Am J Hematol; 2018 Jan; 93(1):91-99. PubMed ID: 29047158
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]